Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Immunterapi til patienter med malignt melanom og hjernemetastaser

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Simonsen, LT, Schmidt, AMS, Øllegaard, TH, Svane, IM, Bastholt, L, Luczak, AA & Schmidt, H 2019, 'Immunterapi til patienter med malignt melanom og hjernemetastaser' Ugeskrift for Laeger, vol. 181, no. 24.

APA

Simonsen, L. T., Schmidt, A. M. S., Øllegaard, T. H., Svane, I. M., Bastholt, L., Luczak, A. A., & Schmidt, H. (2019). Immunterapi til patienter med malignt melanom og hjernemetastaser. Ugeskrift for Laeger, 181(24).

CBE

Simonsen LT, Schmidt AMS, Øllegaard TH, Svane IM, Bastholt L, Luczak AA, Schmidt H. 2019. Immunterapi til patienter med malignt melanom og hjernemetastaser. Ugeskrift for Laeger. 181(24).

MLA

Vancouver

Simonsen LT, Schmidt AMS, Øllegaard TH, Svane IM, Bastholt L, Luczak AA et al. Immunterapi til patienter med malignt melanom og hjernemetastaser. Ugeskrift for Laeger. 2019 Jun 10;181(24).

Author

Simonsen, Line Thing ; Schmidt, Anne Mette Sjørslev ; Øllegaard, Trine Heide ; Svane, Inge Marie ; Bastholt, Lars ; Luczak, Adam Andrzej ; Schmidt, Henrik. / Immunterapi til patienter med malignt melanom og hjernemetastaser. In: Ugeskrift for Laeger. 2019 ; Vol. 181, No. 24.

Bibtex

@article{a26f6e4dcc9d48ccbde89652f358286b,
title = "Immunterapi til patienter med malignt melanom og hjernemetastaser",
abstract = "Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.",
author = "Simonsen, {Line Thing} and Schmidt, {Anne Mette Sj{\o}rslev} and {\O}llegaard, {Trine Heide} and Svane, {Inge Marie} and Lars Bastholt and Luczak, {Adam Andrzej} and Henrik Schmidt",
year = "2019",
month = "6",
day = "10",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "24",

}

RIS

TY - JOUR

T1 - Immunterapi til patienter med malignt melanom og hjernemetastaser

AU - Simonsen, Line Thing

AU - Schmidt, Anne Mette Sjørslev

AU - Øllegaard, Trine Heide

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Luczak, Adam Andrzej

AU - Schmidt, Henrik

PY - 2019/6/10

Y1 - 2019/6/10

N2 - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

AB - Melanoma has a high propensity to form brain metastases, and in this review, we discuss the treatment options for brain metastases. These have previously been sparse, but with the introduction of targeted therapy and checkpoint inhibitors, studies including patients with brain metastases have been published. Recent studies investigating combination of either dabrafenib and trametinib or ipilimumab and nivolumab have proved promising. Based on phase II studies, the most effective treatment for patients with asymptomatic brain metastases seems to be ipilimumab and nivolumab. Symptomatic brain metastases are presently being further investigated.

M3 - Tidsskriftartikel

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 24

ER -

ID: 57728547